Business
AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
About this update from Starpharma Holdings Limited
[{"type":"text","content":"Starpharma Holdings Ltd has released a press release. View Attachment","length":242,"tagName":"div"}]